Rockwell Medical, Inc. to Report First Quarter 2021 Financial and Operating Results on May 17, 2021

Rhea-AI Summary

Rockwell Medical, Inc. (Nasdaq: RMTI) announced a conference call on May 17, 2021, at 4:30 p.m. ET to discuss its financial results for Q1 2021 and recent operational updates. Interested parties can join by calling (877) 383-7438 or (678) 894-3975, using conference ID 7870946, or via a live webcast available on their investor website. The call will feature insights into the company's innovative parenteral iron technology, Ferric Pyrophosphate Citrate, aimed at transforming iron deficiency treatments. Archived webcasts will be available for 30 days post-event.

WIXOM, Mich., May 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 17, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended March 31, 2021, and recent operational highlights.

To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 7870946. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead to transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com 

FAQ

When is Rockwell Medical's next conference call regarding Q1 2021 financial results?

Rockwell Medical will host its next conference call on May 17, 2021, at 4:30 p.m. ET.

What is the purpose of the May 17, 2021, conference call by Rockwell Medical?

The purpose is to discuss Rockwell Medical's financial results for the first quarter of 2021 and recent operational highlights.

How can I access Rockwell Medical's conference call?

You can access the conference call by dialing (877) 383-7438 or (678) 894-3975, and referencing conference ID 7870946, or by watching the live webcast on their investor website.

What innovative technology is Rockwell Medical developing?

Rockwell Medical is developing Ferric Pyrophosphate Citrate, a next-generation parenteral iron technology aimed at treating iron deficiency.

How long will the archived webcast of the conference call be available?

The archived webcast will be available on Rockwell Medical's website for 30 days after the event.